Despite near unanimous objection from its advisory panel, the U.S. Food and Drug Administration (FDA) granted aducanumab approval to treat Alzheimer's disease on June 7, 2021. In a commentary published in Annals of Internal ...
Jun 18, 2021
0
1
Middle-aged people with depressive symptoms who carry a genetic variation called apolipoprotein (APOE) ε4 may be more at risk to develop tau protein accumulations in the brain's emotion- and memory-controlling regions, a ...
Jun 17, 2021
0
4
The U.S. Food and Drug Administration (FDA) recently approved aducanumab, the first treatment that aims to slow the progression of Alzheimer's disease. But approval of the drug has provoked mixed reactions from the scientific ...
Jun 16, 2021
0
5
In a highly anticipated announcement, the U.S. Food and Drug Administration on Monday, June 7, approved the first new drug for Alzheimer's disease in nearly two decades.
Jun 15, 2021
0
2
A new therapy prompts immune defense cells to swallow misshapen proteins, amyloid beta plaques and tau tangles, whose buildup is known to kill nearby brain cells as part of Alzheimer's disease, a new study shows.
Jun 15, 2021
0
564
Alzheimer's disease is the most common form of dementia and is characterized by neurodegeneration in regions of the brain involved in memory and learning. Amyloid beta and tau are two toxic proteins that build up in disease ...
Jun 14, 2021
0
19
Like amyloid plaque, the genetic variant APOE4 has long been associated with Alzheimer's disease, but still little is known about the role the gene plays in the disease process.
Jun 14, 2021
0
18
Affecting over 50 million people, Alzheimer's disease is the most common form of dementia and primarily occurs in people over the age of 65. The pathology of the disease in the brain is mainly characterized by two factors: ...
Jun 11, 2021
0
2
Alzheimer's disease is one of medicine's most elusive thieves, a disease that slowly and irreversibly robs a person's ability to think, reason, remember and maintain normal body functioning. The underlying cause of Alzheimer's ...
Jun 10, 2021
1
9
The U.S. Food and Drug Administration has approved the first new drug to treat Alzheimer's disease in nearly two decades, in a controversial decision that left the agency defending its reputation and its science.
Jun 08, 2021
0
0
